Actively Recruiting
Evaluating COMP360 Psilocybin for Post-Traumatic Stress Disorder A Multicentre, Randomized, Double-Blind Controlled Trial With Open Label Extension
Led by COMPASS Pathways · Updated on 2026-10-23
300
Participants Needed
10
Research Sites
43 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating COMP360, a lab-made version of the naturally occurring compound psilocybin, to see if it can reduce symptoms of post-traumatic stress disorder PTSD. This study is a phase 2b3 clinical trial involving participants diagnosed with PTSD at least six months prior. The trial is randomized, double-blind, and includes an open-label extension to investigate the safety, tolerability, and effectiveness of different doses. Participants receive COMP360 psilocybin at varying doses of 1 mg, 10 mg, or 25 mg, administered alongside monitoring and support from a trained study team. The study compares the effects of these doses using a parallel design, with the primary focus on how symptoms change by week 8 after treatment. The intervention is combined with support throughout the study to observe participant responses. During the trial, participants will undergo assessments to measure PTSD symptom severity using the CAPS-5 scale from baseline through week 8. The study includes regular monitoring and evaluation of safety and tolerability. Participation involves multiple visits over the study period, with close observation by the research team to track symptom changes and any side effects. The entire study is expected to complete by September 2029.
CONDITIONS
Brief Title
Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
Research Team
W
www.redefineptsdstudy.com Redefine Study Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here